Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000285287 is a **pseudogene** classified as "Novel pseudogene similar to avian transmembrane protein 180." Pseudogenes are genomic DNA sequences similar to protein-coding genes but contain disabling mutations such as frameshifts or premature stop codons that prevent translation into a functional protein. The majority of pseudogenes accumulate mutations and do not have an active biological function. However, a small minority in some contexts may have regulatory roles as noncoding RNAs, such as acting as microRNA decoys or generating regulatory siRNAs, though there is no evidence of such a function for this specific pseudogene[1][3][4]. It is not considered a conventional therapeutic target, and drugs do not target it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel pseudogene similar to avian transmembrane protein 180 (ENSG00000285287).